Replies to post #202478 on Biotech Values

[mcbio]

I think expanding the patients who can receive stem cell transplants is one area where these switches are useful. In that area, the switch is actually driving the technology unlike in the CAR-T space.

I think you're essentially referring to what is in fact BLCM's lead platform (not the CAR-T platform).